From biomedcentral.com
()
Rimonabant
Rimonabant was not approved by the FDA due to concerns about suicidal tendencies in patients. Sanofi-Aventis had hoped to release Rimonabant as a weight loss drug.
Background:
The cannabinoid-1 receptor blockers have been proposed in the management of obesity and obesity-related liver diseases (fatty liver as NAFLD or NASH). Due to increasing number of patients to be potentially treated and the need to assess the advantage of this treatment in terms of risk/benefit, we analyze the side events reported during the treatment with rimonabant by a systematic review and meta-analysis of all randomized...
More perspectives...
Rimonabant is the first CB1 receptor inhibitor available in the Brazilian market. This new drug has been approved for the treatment of obese or overweight patients associated with cardiovascular risk factors. In this article it is compared the effects of rimonabant treatment in obese patients with cardiovascular risk factors to usual obesity pharmacological treatment.
More perspectives...
From biomedcentral.com
()
Super buy cheap RIMONABANT SVERIGE Shipped C.o.d
* Cheapest Website to buy,BEST QUALITY for Brand and Generic Medications FDA Approved!
* We provide only Original HIGH QUALITY PHARMACEUTICALS Products online!
* FEDEX overnight Free Shipping WORLDWIDE No extra Costs!
* DISCREET packaging...
More perspectives...
From technologyquestions.com
()
NEW YORK — Drug developer Sanofi-Aventis said Monday a U.S. district court dismissed a shareholder lawsuit against the company over its diet drug Acomplia, which failed to gain Food and Drug Administration approval for U.S. sale.
More perspectives...
From personalinjurylawnews.com
()
Sanofi-Aventis: Zimulti US Class Action Suit DismissedWall Street JournalAt the time, the European Medicines Agency had concerns Acomplia carried patient risk of depression, anxiety and stress disorders which outweighed the ...Shareholder lawsuit over Sanofi's Acomplia dismissedFiercePharmaSanofi-Aventis: US court dismisses lawsuitBusinessWeekCleary Gottlieb Wins Dismissal of Securities Class Action Against ...Am Law Litigation Dailyall 13...
More perspectives...
From news.google.com
()
Shareholder lawsuit over Sanofi's Acomplia dismissedFiercePharmaZimulti had been marketed as Acomplia in 18 European countries since 2006, but was pulled from European markets in October 2008 after an EMEA panel ...Sanofi-Aventis: US court dismisses lawsuitBusinessWeekSanofi-Aventis: Zimulti US Class Action Suit DismissedWall Street JournalCleary Gottlieb Wins Dismissal of Securities Class Action Against ...Am Law Litigation Dailyall 13 news...
More perspectives...
From news.google.com
()
Acomplia (Rimonabant) is the latest drug manufactured by Sanofi-Aventis, a French pharmaceutical firm. It was approved for sale in the United Kingdom and European Union market last June. It is prescribed by doctors as a weight-loss pill and a cure for obesity. Acomplia works by suppressing the appetite in patients, thereby lowering calorie intake and inducing weight-loss. Together with appetite suppression, it also produces a smoking cessation...
More perspectives...
From ezinearticles.com
()
Written by
timawa
on
From:
lose-weightblog.com
Written by
timawa
on
From:
lose-weightblog.com
Written by
timawa
on
From:
lose-weightblog.com
Written by
affiliatecoach
on
